How big is AbCellera Biologics, Inc.?

As of Jun 18, AbCellera Biologics, Inc. has a market capitalization of 931.27 million, with net sales of 23.12 million and a net profit of -167.87 million over the latest four quarters. The company has shareholder's funds of 1,056.08 million and total assets of 1,360.55 million as of Dec 24.

Market Cap: <BR>As of Jun 18, AbCellera Biologics, Inc. has a market capitalization of 931.27 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, AbCellera reported net sales of 23.12 million and a net profit of -167.87 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company has shareholder's funds amounting to 1,056.08 million and total assets of 1,360.55 million.

What does AbCellera Biologics, Inc. do?

AbCellera Biologics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $46 million as of March 2025. It has a market cap of $931.27 million and key metrics indicating it is currently loss-making with no dividend yield.

Overview:<BR>AbCellera Biologics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -46 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 931.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.61 <BR>Return on Equity: -16.41% <BR>Price to Book: 0.91 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold AbCellera Biologics, Inc.?

Is AbCellera Biologics, Inc. overvalued or undervalued?

As of May 4, 2023, AbCellera Biologics, Inc. is considered risky due to overvaluation indicators like a Price to Book Value of 0.71 and negative EV to EBITDA of -0.45, despite a strong year-to-date return of 61.09%, while its long-term performance shows a decline of -54.4%.

As of 4 May 2023, the valuation grade for AbCellera Biologics, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.71 and an EV to Sales ratio of 4.44, which suggests that the market is pricing the company at a premium compared to its asset value and sales generation capabilities. Additionally, the negative EV to EBITDA of -0.45 and ROCE of -81.17% further highlight the challenges the company faces in generating returns.<BR><BR>In comparison to its peers, AbCellera's valuation ratios are concerning; for instance, Arcellx, Inc. has a significantly higher EV to EBITDA of -16.8112, while CymaBay Therapeutics, Inc. shows an even more negative EV to EBITDA of -34.0912. This positions AbCellera in a risky category alongside other companies struggling with profitability. Notably, the company has outperformed the S&P 500 with a year-to-date return of 61.09% compared to the index's 12.22%, but its long-term performance over three years shows a decline of -54.4%, which raises further concerns about its sustainability and future growth prospects.

Is AbCellera Biologics, Inc. technically bullish or bearish?

As of September 11, 2025, AbCellera Biologics, Inc. shows a bullish technical trend supported by positive MACD, Bollinger Bands, and moving averages, significantly outperforming the S&P 500 with a year-to-date return of 61.09% compared to 12.22%.

As of 11 September 2025, the technical trend for AbCellera Biologics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands indicate a bullish stance. Daily moving averages also confirm a bullish trend. The KST shows a bullish signal on the weekly and mildly bullish on the monthly. However, the RSI does not provide any signals on both time frames, and the Dow Theory indicates a mildly bullish stance on the weekly and monthly. <BR><BR>In terms of performance, AbCellera has outperformed the S&P 500 significantly year-to-date with a return of 61.09% compared to the S&P 500's 12.22%, and over the past year, it has returned 71.64% versus 17.14% for the index. Overall, the current technical stance is bullish with strong indicators supporting this view.